nature portfolio

Corresponding author(s):	Edwin Antony
Last updated by author(s):	Sep 22, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

< ∙	トつ	1		Ηı	\sim
.)	ıa	ш	15	u	CS

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
\boxtimes	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X	A description of all covariates tested
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\times	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>

Data collection

cryoEM:

Structure Determination:

Fluorescence: Steady-state fluorescence data were collected on an PC1 fluorimeter (ISS Inc.) using the instrument-associated Vinci 3 software. TIRF microscopy

Stopped Flow: Stopped flow kinetics data were collected using a SX-20 instrument (Applied Photophysics Inc.) and instrument-associated software provided by Applied Photophysics (Pro-Data SX ver.2.5.1852.0).

XL-MS and HDX-MS: In Mass Spectrometry based deuterium exchange experiments, peptides were identified using MassHunter Qualitative Analysis, version 6.0 (Agilent Technologies), Peptide Analysis Worksheet (ProteoMetrics LLC), and Pep-tideShaker, version 1.16.42, paired with SearchGUI, version 3.3.16 (CompOmics).

AUC: Analytical ultracentrifugation experiments were collected using the instrument associated software (Beckman Inc) and exported data were fit and analyzed using SEDFIT.

Mass Photometry:

Gel Imaging: Gels were scanned using an iBright-1500 imager (Thermo Fisher Scientific) and acquired using iBright software (ver.3.0.1). Circular Dichroism: Circular Dichroism data were collected on a Chirascan V100 instrument (Applied Photophysics Inc) using the associated Pro-Data Chirascan software (ver.4.7.0.194).

Single-molecule analysis: We have uploaded the code for single molecule analysis in Github. Here is the link: https://github.com/ChaddaRah/Single-Molecule-Trajectory-Analyzer_RahulChadda.https://github.com/ChaddaRah/Single-Molecule-Trajectory-Analyzer_RahulChadda.
Quantitative Date: Numerical data were exported and analyzed and fitted using GraphPad Prism 9 (Ver. 9.4.0 (673)) or Kaleidagraph (Ver. 4.5) Fluorescence: Steady-state fluorescence data were analyzed using GraphPad Prism 9 (Ver. 9.4.0 (673)).
HDX-MS: The Mass Spectrometry based deuterium exchange experiments, peptides were identified using MassHunter Qualitative Analysis, version 6.0 (Agilent Technologies), Peptide Analysis Worksheet (ProteoMetrics LLC), and Pep-tideShaker, version 1.16.42, paired with SearchGUI, version 3.3.16 (CompOmics). Stopped Flow: Stopped flow data were analyzed using Kaleidagraph (Ver. 4.5).

XL-MS: Crosslinks were then determined using Spectrum Identification Machine (SIMXL 1.5.5.2).

AUC:

Data

Data analysis

Policy information about availability of data

cryoEM:

Structure Determination:

TIRF microscopy

Mass Photometry:

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The coordinates for the Rad52 structure are available in the PDB with code 8G3G and the Cryo-EM maps are available in EMBD with code EMD-29695. The source data for all experiments shown are provided as a Source Data file. Constructs for protein expression are available from the corresponding author upon request.

Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation)</u>, <u>and sexual orientation</u> and <u>race</u>, <u>ethnicity</u> and <u>racism</u>.

Reporting on sex and gender	N/A
Reporting on race, ethnicity, or other socially relevant groupings	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
∑ Life sciences	Behavioural & social sciences	Ecological, evolutionary & environmental sciences	
The second secon			

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.		
Sample size	All experiments were repeated a minimum of three times with atleast two independent protein preparations.	
Data exclusions	No data collected were excluded from analysis.	
Replication	Experiments were repeated n=3 or more independently.	
Randomization	N/A	
Blinding	N/A	

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Methods	
n/a	Involved in the study	n/a	Involved in the study
\boxtimes	Antibodies	\boxtimes	ChIP-seq
\boxtimes	Eukaryotic cell lines	\boxtimes	Flow cytometry
\boxtimes	Palaeontology and archaeology	\boxtimes	MRI-based neuroimaging
\boxtimes	Animals and other organisms		
\boxtimes	Clinical data		
\boxtimes	Dual use research of concern		
\boxtimes	Plants		